Press Release

Cancer Biologics Market to grow with a CAGR of 7.17%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Cancer Biologics Market.

 

According to TechSci Research report, “Global Cancer Biologics Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Cancer Biologics Market has valued at USD 94.10 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.17% through 2028.  This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. Targeted therapies are a significant driver of demand in the Global Cancer Biologics Market. Targeted therapies, a subset of cancer biologics, are designed to specifically interfere with the molecular and genetic pathways that drive cancer growth and progression. They are highly effective in treating various cancer types, and their specificity makes them a preferred choice for many patients. Targeted therapies are at the forefront of the precision medicine revolution in oncology. By identifying specific genetic mutations, protein markers, or other biomarkers in a patient's tumor, oncologists can select the most appropriate targeted therapy. This personalized approach often results in more effective treatment and fewer side effects. Targeted therapies can be highly effective in blocking the signals that promote cancer growth. This leads to a higher response rate, increased progression-free survival, and improved overall survival for many patients. Unlike traditional chemotherapy, which can affect both cancer and healthy cells, targeted therapies are more selective. They primarily target cancer cells, which reduces the severity and frequency of side effects, leading to a better quality of life for patients. Ongoing research and development efforts continually identify new therapeutic targets for cancer treatment. The discovery of novel targets drives the development of new targeted therapies, expanding the range of available treatment options.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Cancer Biologics Market.”

 

 Oncolytic viruses and next-generation sequencing (NGS) technologies have significantly improved our comprehension of the genetic underpinnings of cancer and facilitated the adoption of personalized medicine strategies. Liquid biopsies offer a less intrusive substitute for conventional tissue biopsies, serving to monitor treatment efficacy, identify minimal residual disease, and pinpoint mechanisms of resistance. In January 2020, Roche has submitted a supplemental biologics license application (sBLA) to the US Food and Drug Administration (FDA) for the use of Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of unresectable hepatocellular carcinoma (HCC), a type of liver cancer. This application aims to gain approval for utilizing the combination in patients who have not previously received systemic therapy. Tecentriq is a monoclonal antibody that targets PD-L1, and Avastin is a biologic antibody that acts on the vascular endothelial growth factor (VEGF) protein. By combining these two drugs, the goal is to enhance the immune system's efficacy in combating cancer. Resistance and response variability are significant challenges in the Global Cancer Biologics Market. These challenges have wide-ranging implications for the development, clinical use, and effectiveness of cancer biologics. Some cancer patients exhibit innate resistance, meaning that their cancer cells are inherently less responsive to treatment. Acquired resistance can develop over time, making initially effective treatments less so. Tumors are often genetically heterogeneous, meaning that different parts of the tumor may have distinct genetic profiles. This can result in variable responses to treatment, with some regions of the tumor being resistant. Patients may respond differently to cancer biologics due to factors such as genetics, overall health, and the presence of other medical conditions. Response can vary widely among individuals. Cancer cells have the capacity to adapt to treatment over time, developing mechanisms that enable them to evade the effects of the biologic therapy. This can result in treatment failure and disease progression. Identifying the right patients for specific biologics based on predictive biomarkers is a complex process. Inadequate patient stratification can lead to non-responders and treatment inefficiency.

Global Cancer Biologics Market is segmented based on Products, Application, End User, and by region.  Based on the Product, Global Cancer Biologics Market is segmented into Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune Checkpoint Inhibitors. Cytokine-based immunotherapy is a type of cancer treatment that harnesses the power of cytokines, which are small signaling proteins produced by immune cells, to stimulate or modulate the immune system's response against cancer. Cytokines play a critical role in regulating immune cell activity and communication. When used as cancer therapy, they aim to enhance the immune response, promoting the body's ability to identify and destroy cancer cells. Two key cytokines used in this type of immunotherapy are Interferons and Interleukins. Interferons are proteins produced by immune cells in response to infections or tumors. There are three main types: alpha, beta, and gamma interferons. Interferon-based immunotherapy often involves the use of interferon-alpha, which is used to treat certain types of cancer, such as melanoma, renal cell carcinoma, and some leukemias. Based on Region, North America held the largest share in the Global Cancer Biologics Market. The United States and Canada are home to a significant number of pharmaceutical companies with extensive experience in biologics development. These companies have the resources and expertise to bring new biologics to market. In North America, many patients have access to health insurance that covers the cost of expensive cancer biologics. This encourages the use of these therapies. The region has strong healthcare education and public awareness programs that help in early cancer detection and the understanding of biologic treatment options. North America has a relatively high per capita income, which can support the affordability of biologics. The region fosters collaboration between academic institutions, industry, and healthcare providers, leading to advancements in cancer biologics.

 

Some of the major companies operating in the Global Cancer Biologics Market include:

  • Roche Holding AG
  • Novartis AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • AbbVie Inc.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.


“Certain areas, particularly in North America, are projected to exert significant demand for Cancer Biologics. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Cancer Biologics Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Cancer Biologics Market by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune Checkpoint Inhibitors), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others), by End User (Hospitals & Clinics, Ambulatory Care Centers, Others),), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Cancer Biologics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Cancer Biologics Market.


 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com

Relevant News